NeuroMetrix, Inc. to Present at the Ninth Annual Growth Conference of Needham & Company, LLC on Thursday, January 11, 2007.

WALTHAM, Mass. -- NeuroMetrix, Inc. (NASDAQ: NURO), a medical device company focused on the development and sale of proprietary products used to diagnose neuropathies, announced today that it is scheduled to present at the Ninth Annual Growth Conference of Needham & Company, LLC at The New York Palace Hotel in New York City at 3:30pm (EST) on Thursday, January 11, 2007. The audio presentation will be simultaneously available via webcast on the "Investors" home page at http://www.neurometrix.com.

Shai Gozani, MD, PhD, NeuroMetrix Chief Executive Officer, will be presenting at the conference. Dr. Gozani will provide an overview of NeuroMetrix and will provide an update on operational and strategic matters relating to the business.

About NeuroMetrix

NeuroMetrix is a medical device company that is establishing a new standard of care through the design, development and sale of proprietary products used to help physicians diagnose and treat neuropathies and neurovascular disorders. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or associated with diabetes, low back pain and carpal tunnel syndrome, as well as other clinical disorders. The NC-stat System, the Company's neuropathy diagnostic system, has been on the market since May 1999 and is used in over 4,500 physician's offices and clinics in the United States. Diabetic retinopathy is a common neurovascular complication of diabetes and the leading cause of blindness among working age adults. The Company has exclusive rights in the U.S. physician office arena to market the DigiScope, which is a retinopathy detection system specifically designed for use by primary diabetes care physicians.